Floatz logo

Venetoclax

Chronic Myelomonocytic Leukemia

Servier Bio-Innovation LLCSmall moleculePhase 2/3Active
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
73/ 100

Competitive context

97 Active assets in the Chronic Myelomonocytic Leukemia cohort.

Asset / SponsorPhaseRating
Pevonedistat
Takeda
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 2BB
Evomela
City of Hope Medical Center
Phase 2BB
Idarubicine
Fred Hutchinson Cancer Center
Phase 3BB
Astx727
Taiho Oncology, Inc.
Phase 3BB

View all 50 →

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →